Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://mariyahnsmc048372.designi1.com/63544262/novo-nordisk-s-retatrutide-australia-a-new-breakthrough-for-obesity-treatment